Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans What is the warranty period of a normal scan? by Hachamovitch, Rory et al.
Cardiac Imaging
Determinants of Risk and its Temporal Variation in
Patients With Normal Stress Myocardial Perfusion Scans
What Is the Warranty Period of a Normal Scan?
Rory Hachamovitch, MD, MSC, FACC,* Sean Hayes, MD,† John D. Friedman, MD, FACC,†
Ishac Cohen, PHD,† Leslee J. Shaw, PHD,‡ Guido Germano, PHD, MBA, FACC,†
Daniel S. Berman, MD, FACC†
Los Angeles, California; and Atlanta, Georgia
OBJECTIVES The aim of this study was to determine the predictors of risk and the temporal characteristics
of risk associated with normal myocardial perfusion single photon emission computed
tomography (MPS).
BACKGROUND No empiric data exist regarding predictors of risk after normal MPS and their temporal
characteristics.
METHODS Follow-up (mean: 665  200 days, 96% complete) of 7,376 consecutive patients with normal
exercise or adenosine MPS identified 78 hard events (HE) (45 cardiac deaths, 33 non-fatal
myocardial infarction; 1.1% cumulative HE rate, 0.6%/year). Cox proportional hazards
analysis was used to identify predictors of HE. Parametric survival analysis was used to model
predicted time to HE.
RESULTS The HE rates were greater in patients with versus without previous coronary artery disease
(CAD). The Cox proportional hazards model identified pharmacologic stress, known CAD,
diabetes mellitus (DM), male gender, and increasing age, with interactions between stress
type and previous CAD (lower risk in patients without previous CAD undergoing exercise
stress vs. all others) and between DM and gender (higher risk in DM females vs. all others)
as the model most predictive of HE. The highest risk subgroups had a maximal event rate of
1.4% to 1.8%/year. Parametric survival models revealed that in patients without previous
CAD the level of risk was uniform with time, but in patients with known CAD, risk increased
with time (e.g., risk in the first year was less than in the second year, hence, a dynamic
temporal component of risk was present).
CONCLUSIONS Multiple clinical factors add incremental prognostic value in patients with normal MPS,
affecting their risk and its temporal pattern, and may alter the appropriate timing of repeat
testing, hence establishing the existence of a “warranty” period for normal MPS
studies. (J Am Coll Cardiol 2003;41:1329–40) © 2003 by the American College of
Cardiology Foundation
Stress myocardial perfusion single photon emission com-
puted tomography (MPS) plays an important role in risk
assessment of patients with known or suspected coronary
artery disease (CAD). It has been shown to risk stratify a
variety of patient populations and, when incorporated in an
overall testing strategy, lower the overall cost and enhance
the effectiveness of testing (1–3). The low risk associated
with normal MPS is an important component of these
findings—by identifying patients at sufficiently low risk for
subsequent events, they can be safely managed medically,
and additional, costly testing and interventions can be
avoided (1–4).
To date, most studies examining risk after a normal MPS
have reported rates of hard events (HE) (cardiac death or
nonfatal myocardial infarction [MI]) of 1% per year of
follow-up. Many have claimed that this low risk is indepen-
dent of imaging type (single photon emission computed
tomography [SPECT] vs. planar), stress performed (exer-
cise vs. pharmacologic), isotope used, clinical characteristics,
or previous history of CAD (1–3,5–13). However, studies of
patients undergoing pharmacologic stress, a population at
higher risk, and more comorbidities than patients undergo-
ing exercise have reported HE rates of 1.3% to 2.7% per year
(14–18), suggesting that underlying clinical risk and previ-
ous CAD may influence event rates after a normal MPS.
Thus, although MPS provides incremental prognostic in-
formation over clinical information alone, it appears that
clinical information also yields incremental prognostic value
over MPS data after normal MPS. Further, if these clinical
and historical factors also affect the temporal characteristics
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of this risk, how long risk remains low after a normal MPS
may be dictated by clinical and historical characteristics.
To date, MPS prognosis studies have expressed results as
cumulative event rates, and normal MPS are considered to
indicate low risk if the event rate is below 1% per year.
Knowledge of this event rate alone, however, is potentially
misleading. For example, while an event rate of 1% per
year after a normal MPS may be the result of a constant
1% per year event rate over the follow-up interval, it may
also result from an event rate of 1% during the first year
and a markedly increased event rate later in the follow-up
period. Similarly, even an event rate of 1% per year over
more than one year does not exclude the possibility that risk
was exceedingly low initially, but increased with time, and
risk was not 1% later. These temporal characteristics of
risk (how risk changes with time) are as yet undefined but
may be important in determining MPS test performance.
The goals of the current study were to: 1) determine
whether clinical factors alter risk for HE after normal MPS;
2) identify the predictors of increased risk and shortened
survival time in patients with normal MPS; and 3) deter-
mine the impact of these predictors on the length of time
that patients remain at low risk after the index normal MPS,
hence defining whether a “warranty” period exists.
METHODS
Study population. We identified 16,187 consecutive pa-
tients who underwent dual-isotope MPS between January 1,
1991 and March 27, 1997 (Fig. 1). Patients with valvular
heart disease or primary cardiomyopathy were excluded
from this study. Of the initial population, 712 patients
(4.4%) were lost to follow-up. Of the remaining patients,
8,019 were excluded because of abnormal scans, leaving a
study population of 7,456 patients with normal MPS. Of
these, 80 patients who underwent SPECT within 90 days
after percutaneous transluminal coronary angioplasty
(PTCA) were excluded owing to the relative instability of
their disease, thus leaving 7,376 patients in this study (48%
of the follow-up population). Patients with previous MI or
revascularization were considered to have known CAD.
Rest thallium (Tl)-201 imaging. All patients underwent
stress dual-isotope SPECT as previously described (19,20).
Whenever possible, beta-blockers and calcium channel an-
tagonists were terminated 48 h before testing. Initially,
Tl-201 (2.5 to 3.5 mCi) was injected intravenously at rest,
with dose variation based on patient weight, and rest Tl-201
imaging was initiated 10 min afterward.
Exercise stress protocol. All patients performed a
symptom-limited treadmill exercise test using standard
protocols. At near maximal exercise, a 20- to 30-mCi dose
of technetium (Tc)-99m sestamibi was injected (actual
patient dose varied with patient weight) and exercise con-
tinued for 1 min after injection. The Tc-99m sestamibi
SPECT imaging was begun 15 to 30 min after isotope
injection (19).
Adenosine stress protocol. Patients were instructed not to
consume coffee or other products containing caffeine for
24 h before MPS. After rest Tl-201 SPECT, infusion (140
g/kg/min for 6 min) was performed, and Tc-99m sesta-
mibi was injected at the end of the third minute of infusion.
Single photon emission computed tomography was initiated
approximately 60 min after adenosine infusion (19).
During both types of stress, 12-lead electrocardiographic
recording was performed each minute of stress with contin-
uous monitoring of leads aVF, V1, and V5. Blood pressure
was measured and recorded at rest, at the end of each
exercise stage, and at peak exercise. Maximal degree of
ST-segment change at 80 ms after the J point of the
electrocardiogram (ECG) was measured and assessed as
horizontal, upsloping, or downsloping.
SPECT acquisition protocol. Myocardial perfusion single
photon emission computed tomography was performed as
previously described (19,20) using a circular or elliptical
180° acquisition for 64 projections at 20 s per projection.
Images were subject to quality control measures as previ-
ously described (20). No attenuation or scatter correction
was used. After filtered back-projection, short-axis, vertical,
and horizontal long-axis tomograms were generated.
Image interpretation. Semiquantitative visual interpreta-
tion used short-axis and vertical long-axis tomograms di-
Abbreviations and Acronyms
CAD  coronary artery disease
ECG  electrocardiogram
ETT  exercise tolerance test
HE  hard event
MI  myocardial infarction
MPHR  maximal predicted heart rate
MPS  myocardial perfusion single photon emission
computed tomography
PTCA  percutaneous transluminal coronary
angioplasty
SPECT  single photon emission computed tomography
Tc  technetium
Tl  thallium
Figure 1. Outline of patient selection. PTCA percutaneous transluminal
coronary angioplasty; SPECT single photon emission computed tomog-
raphy.
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vided into 20 segments (2,4). Each segment was scored by
consensus of two experienced observers using a five-point
scoring system (0  normal, 1  equivocal, 2  moderate,
3  severe reduction of uptake, and 4  absence of
detectable tracer uptake). A summed stress score (SSS) was
obtained by adding the scores of the 20 segments of the
stress sestamibi images; SSS 4 was considered normal
(2,4).
Patient follow-up. Patient follow-up was performed by
scripted telephone interview by individuals blinded to the
patient’s test results, as previously described (1,2,4). Events
were defined as either cardiac death (confirmed by review of
death certificate, hospital chart, or physician’s records) or
non-fatal MI (documented by appropriate cardiac enzyme
and electrocardiographic changes). The mean follow-up
interval was 665  200 days.
Likelihood of CAD. The pre- and post-exercise tolerance
test (ETT) likelihood of CAD were calculated using
CADENZA (Advanced Heuristics Inc., Bainbridge Island,
Washington), a software package utilizing Bayesian analysis
of clinical data (21). The pre-scan likelihood of CAD was
defined as the pre-ETT likelihood of CAD in patients who
underwent adenosine stress and the post-ETT likelihood in
patients who underwent exercise. In patients with known
CAD, this calculated likelihood is modified to be a likeli-
hood of ischemia.
Statistical analysis. Comparisons between patient groups
were performed using a chi-square test for categorical
variables and a one-way analysis of variance, with a Bon-
ferroni correction where appropriate. Categorical variables
were described as a frequency, and continuous variables were
described as a mean  SD (25th and 75th percentiles).
Observed, attributable, and relative risks were calculated.
Attributable risk is defined as the risk in exposed individuals
that can be attributed to the exposure. This measure is
derived by subtracting the event rate in nonexposed persons
from the corresponding rate among exposed individuals.
Relative risk is defined as the ratio of the risk among those
exposed to the risk among those not exposed. A p value of
0.05 was considered significant.
Cox proportional hazards analysis was used to determine
the predictors of adverse outcomes, and parametric survival
models (accelerated failure time models) were used to
identify which variables influenced time to event and to
estimate risk-adjusted event rates at specific time intervals
and the length of time to specific risk thresholds. First,
models were developed to identify variables most predictive
of events, using a stepwise approach employing the most
significant univariable predictors from Tables 1 and 2.
Variables were first categorized into the following groups: 1)
cardiac risk factors (age, hypertension, diabetes, pre-scan
likelihood); 2) abnormal rest ECG, stress type, medications,
symptoms; and 3) in patients with known CAD, historical
variables. The most predictive variables from each of these
were entered into a final model. For parametric survival
analyses, separate models were developed for patients with
versus without previous CAD. Based on the distribution of
survival times in our cohort, a Weibull distribution was
selected for the parametric models (22,23). All multivariable
modeling was performed using S plus 2000 (Insightful
Table 1. Characteristics of Patients With No History of Previous CAD
Measure Observed Risk Attributable Risk Relative Risk CoxPH
End Point CD HE CD HE CD HE HR
Male gender 51% (3,070) 0.3% 0.5% 0.4% 0.4% 0.43 0.55 0.59
Age (yrs) 61  13 (51–71) 1.3% 1.6% 1.1% 1.3% 6.50 5.30 1.09
Exercise stress 77% (4,667) 0.1 0.3 1.4% 1.7% 0.07 0.15 0.18
Cardiac risk factors
Hypertension 41% (2,475) 0.6% 0.9% 0.2% 0.4% 1.50 1.80 1.61
DM 9.6% (578) 1.6% 2.2% 1.3% 1.7% 5.33 4.40 4.20
Family history 41% (1,349) 0.1% 0.3% 0.5% 0.5% 0.17 0.37 0.39
Smoking 13% (814) 0.2% 0.7% 0.3% 0% 0.40 0.10 1.12
Increased cholesterol symptoms 41% (2,486) 0.4% 0.6% 0.1% 0.2% 0.80 0.75 0.76
Asymptomatic 33% (1,989) 0.4% 0.4% — — — 0.5
NACP 29% (1,757) 0.2% 0.5% 0.2% 0.1% 0.50 1.25 0.65
Atypical angina 26% (1,595) 0.6% 0.9% 0.2% 0.5% 1.50 2.25 1.52
Typical angina 8% (490) 0.4% 0.8% 0 0.4% 1.00 2.00 1.17
Dyspnea 4% (215) 2.8% 2.8% 2.4% 2.4% 7.00 7.00 4.97
Likelihood of CAD 0.22  0.41
(0.03–0.42)
1.0% 1.5% 0.7% 1.1% 3.33 3.75 7.76
Medications
Beta-blockers 6% (366) 0.5% 0.8% 0% 0.1% 1.00 1.14 1.18
CCB 7.4% (450) 0.7% 2.0% 0.3% 1.4% 1.75 3.33 3.43
NTG 3.0% (179) 0% 0.6% 0.5% 0.1% 0 0.86 0.80
Abnormal rest ECG 51% (3,117) 0.7% 1.0% 0.5% 0.7% 3.50 3.33 2.93
Categorical variables are described as % (n), continuous variables as mean  SD (25th, 75th percentiles). Risk is expressed as event rate over follow-up period. Continuous
variables are dichotomized at the level of the 75th percentile, except for determination of hazard ratio based on the Cox proportional hazards model.
CAD  coronary artery disease; CCB  calcium channel blocker; CD  cardiac death; CoxPH  Cox proportional hazards model (univariable); DM  diabetes mellitus;
ECG  electrocardiogram; HE  hard event; HR  hazard ratio; NACP  nonanginal chest discomfort; NTG  nitroglycerin.
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Corp., Seattle, Washington). When appropriate, assump-
tions of linearity, proportional hazards, and multiplicity
were tested (22–24). Patients undergoing revascularization
early after nuclear testing were not censored, because the
revascularization was not related to the result of MPS.
Although the parametric modeling was used to estimate
predicted time to risk and levels of risk at specific time
intervals, the limited number of events in this study com-
promises the accuracy of these estimates, and their purpose
is to illustrate the impact of confounders on time and risk.
The threshold for entry of variables into models was p 
0.10.
RESULTS
Outcome events. A total of 78 HE (45 cardiac deaths and
33 non-fatal MI) occurred, representing a 1.1% cumulative
HE rate (0.6%/year). The 8,019 patients with abnormal
MPS who underwent testing during this time interval
experienced 530 HE (6.6% cumulative HE rate), and the 80
patients with normal studies immediately after PTCA
(excluded from this study) experienced 5 HE (6.3% cumu-
lative HE rate). Thus, the 15,475 patients tested during this
time interval experienced a cumulative HE rate of 4.0%
(613 total HE).
For purposes of analysis, patients with normal MPS were
separated into those without (6,046 patients; 41 HE, 0.7%
cumulative rate) and with known CAD (1,330 patients; 37
HE, 1.3% cumulative rate).
Clinical characteristics. The clinical characteristics of
these two groups are shown in Tables 1 and 2. Patients
without previous CAD were evenly split by gender (Table
1), predominantly underwent exercise, and infrequently had
diabetes or a history of smoking. Intermediate numbers had
hypertension, a family history of CAD, or elevated choles-
terol. About a third were asymptomatic, smaller numbers
had nonanginal chest discomfort or atypical angina, and
fewer had typical angina or dyspnea. The pre-scan likeli-
hood of CAD was low-intermediate. Half had abnormal
rest ECG, and few were using anti-ischemic medications.
Patients with known CAD (Table 2) were more often
male. One-third of patients had nonanginal chest discom-
fort, 28% were asymptomatic, and smaller proportions had
atypical angina, typical angina, or dyspnea. The pre-scan
likelihood of ischemia was low-intermediate. Few patients
were taking anti-ischemic medications.
Univariate predictors of outcomes. The observed, attrib-
utable, and relative risks associated with these clinical
characteristics are shown in Tables 1 and 2. In patients
without known CAD (Table 1), increased age, diabetes, and
dyspnea were associated with a greater observed risk of
cardiac death or HE. The use of calcium channel blockers
was also associated with higher observed risk of HE.
Table 2. Characteristics of Patients With History of Known CAD
Measure Observed Risk Attributable Risk Relative Risk CoxPH
End Point CD HE CD HE CD HE HR
Male gender 56% (739) 0.9% 3.1% 0.7% 0.7% 0.56 1.31 1.37
Age (yrs) 66  12 (59–75) 3.6% 4.3% 3.0% 1.9% 6.19 1.83 1.04
Exercise stress 65% (866) 1.0% 2.9% 0.7% 0.3% 0.60 1.12 1.68
Cardiac risk factors
Hypertension 52% (692) 1.6% 3.0% 0.6% 0.5% 1.69 1.21 1.23
DM 15% (197) 1.5% 3.6% 0.3% 0.9% 1.23 1.34 1.29
Family history 26% (348) 1.4% 3.4% 0.2% 0.9% 1.18 1.35 1.42
Smoking 11% (141) 0.7% 2.8% 0.6% 0.1% 0.53 1.02 0.99
Increased cholesterol 50% (670) 1.0% 2.5% 0.5% 0.5% 0.69 0.84 0.89
Symptoms
Asymptomatic 28% (371) 0.8% 2.4% 0.7% 0.5% 0.55 0.83 0.85
NACP 33% (434) 2.1% 3.8% 1.0% 1.4% 1.99 1.54 1.53
Atypical angina 21% (286) 1.2% 2.3% 0.2% 0.7% 0.86 0.76 0.75
Typical angina 15% (198) 0.5% 2.5% 0.9% 0.3% 0.36 0.89 0.88
Dyspnea 3% (41) 4.9% 4.9% 3.7% 2.2% 4.19 1.80 2.01
Likelihood of ischemia 0.38  0.35
(0.08–0.68)
1.2% 2.1% 0.1% 1.0% 0.90 0.68 0.72
Medications
Beta-blockers 11% (146) 2.1% 3.4% 0.9% 0.7% 1.74 1.27 1.32
CCB 18% (234) 0.9% 3.0% 0.5% 0.3% 0.62 1.09 1.00
NTG 8% (112) 3.6% 3.6% 2.5% 0.9% 3.35 1.32 1.07
Abnormal rest ECG 64% (846) 1.8% 3.4% 1.4% 1.8% 4.29 2.07 2.00
History of angiography 85% (1,127) 1.4% 3.2% 0.9% 2.7% 2.88 6.48 6.81
History of PTCA 26% (350) 1.1% 4.0% 0.2% 1.7% 0.86 1.70 1.70
History of CABG 21% (278) 1.1% 4.3% 0.3% 1.9% 0.81 1.82 1.67
History of MI 34% (455) 1.3% 2.2% 0.1% 0.9% 1.05 0.71 0.67
Categorical variables are described as % (n), continuous variables as mean  SD (25th, 75th percentiles). Risk is expressed as event rate over follow-up period. Continuous
variables are dichotomized at the level of the 75th percentile, except for determination of hazard ratio based on the Cox proportional hazards model.
CABG  coronary artery bypass surgery; MI  myocardial infarction; NACP  nonanginal chest discomfort; PTCA  percutaneous transluminal coronary angioplasty;
Other abbreviations as in Table 1.
1332 Hachamovitch et al. JACC Vol. 41, No. 8, 2003
Duration of Low Risk After Normal SPECT April 16, 2003:1329–40
Attributable risk was greatest for increasing age, exercise (a
protective effect), diabetes, and dyspnea with respect to both
HE and cardiac death. Higher relative risks for HE were
noted for age, diabetes, and symptoms of dyspnea, with
relatively high values present for pre-scan likelihood of
CAD, calcium channel blockers, and abnormal rest ECG.
Strikingly low relative risks were associated with exercise
stress and smoking, and to a lesser extent, with family
history of CAD. The relative risk for cardiac death was low
for exercise and high for diabetes, dyspnea, and age.
In patients with known CAD (Table 2), the clinical
characteristics associated with greater observed risk of HE
or cardiac death included age, hypertension, diabetes, and
dyspnea. The use of beta-blockers and nitrates was also
associated with higher observed risk of HE. Attributable
risk was greatest for age, dyspnea, and nitrate use with
respect to cardiac death and age, abnormal rest ECG, and
previous angiography for HE. Increased relative risk of HE
was noted for age, dyspnea, nitrate use, abnormal rest ECG,
and previous angiography. Low relative risks were associ-
ated with exercise, smoking, hypercholesterolemia, presen-
tation without symptoms, typical angina, and calcium chan-
nel blockers.
Risk and percent maximal heart rate achieved. Of the
5,533 patients who underwent exercise stress, 4,937 (89%)
attained target heart rate (85% of maximal predicted heart
rate [MPHR]). In addition, 7% achieved 80% to 85%, 3%
attained 70% to 80%, and 2.9% achieved 70% of MPHR.
The HE rates in these four subgroups of patients were 0.7%,
0.5%, 1.1%, and 2.9%, respectively. This suggests that
prognostically, achieving 80% of MPHR is sufficient, but
lower MPHR are associated with worse prognosis.
Clinical characteristics and predictors of outcomes as a
function of presenting symptoms. As a function of pre-
senting symptoms (Table 3), significant differences in HE
rates were found in all variables examined except for
smoking and likelihood of CAD. Significant differences
were present as a function of age, gender, type of stress,
hypertension, diabetes, family history, cholesterol levels,
anti-ischemic medication use, and rest ECG.
HE rates in patient subgroups. A significant difference
was present with respect to HE rates between patients with
versus without a history of CAD (p  0.001; 1.4% vs. 0.4%
per year, respectively) (Fig. 2). No such differences were
present as a function of type of stress or patient gender.
Comparing rates of HE in men and women with versus
Table 3. Demographic, Clinical, and Risk Factor Characteristics and Hard Event Rates by Presenting Symptoms in Patients With
No History of Previous CAD
Presenting Symptoms
Asymptomatic NACP Atypical Angina Typical Angina Dyspnea
n (HE rate) 1,989 (0.4%) 1,757 (0.5%) 1,595 (0.9%) 490 (0.8%) 215 (2.8%)
Male gender 66% (1,306) 49% (865) 40% (643) 35% (173) 39% (83)
0.3% (0.6%) 0.7% (1.3%) 0.3% (2.3%) 0.0% (0.3%) 3.6% (1.3%)*
Age (yrs) 22% (428) 21% (377) 26% (407) 25% (122) 48% (104)
1.4% (0.1%) 0.5% (0.3%) 2.5% (0.9%) 2.5% (0.5%) 4.8% (0.3%)*
61  12 60  13 61  13 62  13 69  13*
Exercise stress 79% (1,572) 75% (1,406) 80% (1,201) 73% (357) 61% (131)
0.3% (1.0%) 0.4% (2.8%) 0.2% (6.0%) 0.0% (0.9%) 0.8% (3.0%)*
Hypertension 37% (744) 39% (682) 45% (711) 48% (233) 49% (105)
0.5% (0.3%) 0.6% (0.8%) 1.0% (1.8%) 1.3% (0.5%) 3.8% (0.4%)*
Diabetes mellitus 9% (183) 8% (134) 117 (772) 11% (55) 16% (34)
1.1% (0.3%) 0.0% (0.6%) 3.5% (1.7%) 3.6% (0.6%) 8.8% (0.5%)*
Family history 22% (446) 21% (363) 23% (361) 27% (134) 21% (45)
0.2% (0.5%) 0.3% (1.1%) 0.0% (2.9%) 0.7% (0.6%) 2.2% (0.8%)*
Smoking 13% (264) 14% (242) 13% (213) 13% (66) 13% (29)
0.0% (0.5%) 0.4% (0.7%) 1.9% (3.2%) 1.5% (0.5%) 0.0% (0.7%)
Increased cholesterol 39% (773) 42% (744) 43% (688) 42% (204) 36% (77)
0.4% (0.4%) 0.4% (1.1%) 0.6% (3.6%) 1.5% (0.6%) 1.3% (0.3%)*
Likelihood of CAD 11% (214) 10% (177) 44% (708) 82% 9% (20)
1.9% (0.2%) 1.7% (0.3%) 1.6% (2.6%) 1.0% (0.4%) 5.0% (0.0%)
0.15  0.21 0.16  0.20 0.39  0.28 0.72  0.27 0.15  0.18
Beta-blockers 5.6% (112) 5.5% (97) 6.0% (96) 9.4% (46) 7.0% (15)
1.8% (0.3%) 1.0% (0.9%) 0.0% (3.0%) 0.0% (0.5%) 0.0% (0.9%)*
CCB 5% (107) 6% (108) 8% (133) 15% (75) 13% (27)
0.0% (0.0%) 1.9% (0.5%) 3.8% (0.0%) 1.3% (0.4%) 3.7% (0.8%)*
NTG 0.6% (12) 2.1% (3) 5.0% (80) 8.0% (39) 5.1% (11)
0.0% (0.4%) 0.0% (0.8%) 1.3% (2.9%) 0.0% (0.5%) 0.0% (0.9%)*
Abnormal rest ECG 55% (1,092) 47% (832) 50% (803) 52% (253) 64% (137)
0.7% (0.0%) 0.6% (0.5%) 1.2% (0.0%) 0.8% (0.4%) 4.4% (0.8%)*
For each variable, the values on the upper line represent the frequency of the variable within each symptom category and number of patients [% (n)], the lower line shows the
hard event rate for patients with the variable (and without the variable) over the follow-up interval. Continuous variables are dichotomized at the level of the 75th percentile.
*p  0.05 within categories of presenting symptom.
Abbreviations as in Table 1.
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without diabetes (Fig. 3), diabetic women had a HE rate of
1.8%/year, with lower rates in the other subgroups. No
difference was present in HE rates between men and women
either with or without diabetes. However, a difference was
present between women with versus without diabetes (p
0.007), although no such difference was present in men. No
difference in HE rates was present between patients with
versus without known CAD with adenosine stress (Fig. 4),
but a significant difference was present with exercise stress
(p  0.001).
Multivariable survival analysis. Cox proportional hazards
analysis identified stress type, CAD history, diabetes, gen-
der, and age as the model most predictive of HE. Interac-
tions were present between type of stress and history of
CAD as well as between the presence of diabetes and gender
(Table 4).
The final model for prediction of time to HE in patients
with no previous CAD included age and gender, the
presence of diabetes, and the type of stress. This model
included a nonlinear term for age and an interaction
between gender and diabetes. In patients with previous
CAD, the final model of time to HE included age, gender,
diabetes, and previous catheterization. Significant interac-
tions were present between age and gender and between
diabetes and gender.
As the model for patients with known CAD did not
include stress type but the model for patients without CAD
did, the results of subsequent analyses shown in Tables 5
through 8 will show separate results for exercise and
adenosine stress patients without CAD but a single set of
results in patients with known CAD.
Changes in risk with time: event rates as a function of
increments of follow-up time. To better understand the
temporal change in risk as a function of patient character-
istics, we estimated the predicted HE rate at six-month
intervals for the first two years after the index study (first,
Figure 2. Hard event rates (% per year) in women versus men, patients with versus without history (Hx) of previous coronary artery disease (CAD), and
patients undergoing adenosine versus exercise stress. *p  0.001.
Figure 3. Hard event rates (% per year) in men (black bars) and women (white bars) with (right) versus without (left) diabetes. Numbers under bars
represent number of patients within category. *p  0.007. DM  diabetes mellitus.
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second, third, and fourth 6-month intervals), and summed
these to show predicted event rates in the first versus second
years of follow-up as well as the overall two-year predicted
event rates (Table 5).
In patients with no previous CAD undergoing exercise,
non-diabetic women had very low predicted event rates at
all ages for all six-month intervals examined. These rates
were similarly very low in both diabetic and non-diabetic
men until age 80, at which point event rates were still
relatively low, despite being 2 to 3 times greater than event
rates at younger ages. Diabetic women had predicted HE
rates that were 4- to 5-fold greater, and, by age 80, reached
rates of 1% or more in two of four six-month intervals
examined. Patients undergoing adenosine stress had a sim-
ilar pattern of predicted HE rates (no significant temporal
change with a significant age-related trend), but with
significantly greater absolute rates of HE.
In comparison to patients without previous CAD, pa-
tients with known CAD at the time of SPECT (Table 6)
had a similar pattern of increasing risk with age, but greater
predicted event rates in all time intervals except in the
setting of elderly female diabetics. Patients with known
CAD also differed from patients without previous CAD in
that female diabetics had event rates similar to male diabet-
ics and non-diabetics; however, non-diabetic women had
lower event rates.
The most striking finding in patients with known CAD
was that patient risk increased in all patient subgroups in
each successive time interval. Comparing the first to the
fourth six-month interval, patient risk increased approxi-
mately 2 to 2.5 times, and event rates in the first year were
lower than in the second year. Hence, risk appears to
accelerate over time in patients with known CAD (Fig. 5).
To further understand the temporal characteristics of risk
as a function of patient characteristics, we estimated the
predicted time to 0.5%, 1.0%, 1.5%, and 2.0% risk based on
the multivariable models, as well as the time from the index
study to 0.5% risk, 0.5% to 1.0% risk, 1.0% to 1.5% risk, and
1.5% to 2.0% risk (Tables 7 and 8). The latter was
performed to determine whether the risk of HE changed
over time.
In patients without previous CAD (Table 7), predicted
time to any level of risk was extremely long in men both
with and without diabetes, as well as in non-diabetic
women, until advanced age. In these three patient sub-
groups, time to risk was relatively long (time to 1% risk
occurring well beyond 1 year) even at age 80. In diabetic
women, however, time to risk was significantly shortened at
each age level and reached short intervals (1% risk at 1
year) by age 80. Examining time to each level of risk reveals
that in all four patient subgroups, time to risk shortened
only minimally with increasing risk level, implying that risk
did not change over time.
In patients with known CAD (Table 8), time to any level
of risk was long in non-diabetic women but was relatively
shorter in the three other subgroups at most ages examined
Figure 4. Hard event rates (% per year) in patients without (black bars) versus with (white bars) history of known coronary artery disease undergoing
exercise (left) or adenosine (right) stress. Numbers under bars represent number of patients within category. *p  0.001.
Table 4. Final Cox Proportional Hazards Model for
Hard Events
Factors Chi-Square p Value
Exercise stress (factor  higher order factors) 14.4 0.0008
All interactions 13.7 0.0002
History of CAD (factor  higher order factors) 30.1 0.0001
All interactions 13.7 0.0002
DM (factor  higher order factors) 14.8 0.0006
All interactions 4.8 0.0291
Male (factor  higher order factors) 5.4 0.0672
All interactions 4.8 0.0291
Age (yrs) 26.0 0.0001
Exercise stress * history of CAD
(factor  higher order factors)
13.7 0.0002
DM * male (factor  higher order factors) 4.8 0.0291
Total interaction 18.9 0.0001
Total 81.0 0.0001
“All interactions” refers to the statistical significance of the interactions for each
variable.
Abbreviations as in Table 1.
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Table 5. Predicted Rates of Hard Events by Six-Month Intervals in Patients With No History of Previous CAD
Age
(yrs)
First Six
Months
(%)
Second Six
Months
(%)
Third Six
Months
(%)
Fourth Six
Months
(%)
First Year
(%)
Second Year
(%)
Two-Year
Sum (%)
Exercise stress
Male 50 0.03 0.03 0.05 0.08 0.06 0.13 0.19
Non-DM 60 0.05 0.05 0.06 0.10 0.10 0.16 0.26
70 0.10 0.08 0.13 0.20 0.18 0.33 0.51
80 0.36 0.23 0.35 0.52 0.59 0.87 1.46
Female 50 0.01 0.02 0.03 0.04 0.03 0.07 0.10
Non-DM 60 0.02 0.02 0.03 0.05 0.04 0.08 0.12
70 0.04 0.04 0.06 0.10 0.08 0.16 0.24
80 0.17 0.12 0.19 0.29 0.29 0.48 0.77
Male 50 0.03 0.02 0.04 0.07 0.05 0.11 0.16
DM 60 0.04 0.03 0.05 0.09 0.07 0.14 0.21
70 0.09 0.06 0.11 0.17 0.15 0.28 0.43
80 0.30 0.20 0.31 0.46 0.50 0.77 1.27
Female 50 0.17 0.12 0.19 0.29 0.29 0.48 0.77
DM 60 0.22 0.15 0.23 0.36 0.37 0.59 0.96
70 0.45 0.28 0.41 0.62 0.73 1.03 1.76
80 1.31 0.69 0.97 1.34 2.00 2.31 4.31
Adenosine stress
Male 50 0.12 0.14 0.14 0.14 0.26 0.28 0.54
Non-DM 60 0.15 0.17 0.18 0.18 0.32 0.36 0.68
70 0.27 0.31 0.31 0.32 0.58 0.63 1.21
80 0.70 0.77 0.80 0.81 1.47 1.61 3.08
Female 50 0.08 0.08 0.08 0.09 0.16 0.17 0.33
Non-DM 60 0.10 0.10 0.11 0.12 0.20 0.23 0.43
70 0.17 0.19 0.20 0.21 0.36 0.41 0.77
80 0.44 0.49 0.50 0.52 0.93 1.02 1.95
Male 50 0.13 0.14 0.15 0.15 0.27 0.30 0.57
DM 60 0.16 0.18 0.18 0.19 0.34 0.37 0.71
70 0.29 0.31 0.33 0.33 0.60 0.66 1.26
80 0.73 0.80 0.83 0.84 1.53 1.67 3.20
Female 50 0.41 0.46 0.47 0.49 0.87 0.96 1.83
DM 60 0.51 0.57 0.60 0.60 1.08 1.20 2.28
70 0.92 1.01 1.03 1.05 1.93 2.08 4.01
80 2.34 2.52 2.55 2.55 4.86 5.10 9.96
CAD  coronary artery disease; DM  diabetes mellitus.
Table 6. Predicted Rates of Hard Events by Six-Month Intervals in Patients With History of Known CAD
Age
(yrs)
First Six
Months
(%)
Second Six
Months
(%)
Third Six
Months
(%)
Fourth Six
Months
(%)
First Year
(%)
Second Year
(%)
Two-Year
Sum (%)
Male 50 0.33 0.56 0.70 0.80 0.89 1.50 2.39
Non-DM 60 0.39 0.66 0.82 0.94 1.05 1.76 2.81
70 0.46 0.77 1.00 1.10 1.23 2.10 3.33
80 0.54 0.91 1.14 1.30 1.45 2.44 3.89
Female 50 0.01 0.01 0.01 0.02 0.02 0.03 0.05
Non-DM 60 0.03 0.05 0.07 0.08 0.08 0.15 0.23
70 0.15 0.25 0.32 0.36 0.40 0.68 1.08
80 0.70 1.17 1.45 1.65 1.87 3.10 4.97
Male 50 0.34 0.57 0.72 0.83 0.91 1.55 2.46
DM 60 0.41 0.71 0.87 1.00 1.12 1.87 2.99
70 0.53 0.90 1.11 1.27 1.43 2.38 3.81
80 0.68 1.15 1.41 1.62 1.83 3.03 4.86
Female 50 0.44 0.74 0.92 1.06 1.18 1.98 3.16
DM 60 0.45 0.76 0.95 1.09 1.21 2.04 3.25
70 0.46 0.79 0.97 1.11 1.25 2.08 3.33
80 0.48 0.80 1.00 1.14 1.28 2.14 3.42
CAD  coronary artery disease; DM  diabetes mellitus.
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(rate of risk 1% per year). Examining the time intervals
between levels of risk, each 0.5% level of predicted risk
occurred at shortening intervals, indicating an increase in
risk with time after a normal MPS in patients with known
CAD (p  0.001).
DISCUSSION
We followed a cohort of patients after normal MPS to
determine 1) whether clinical factors altered the risk for
HE, 2) which factors were predictive of risk, and 3) whether
a significant change in risk over time occurred after a normal
MPS. Univariable analysis revealed that HE rates were
greater in diabetic versus non-diabetic women. Compared
with patients without previous CAD undergoing exercise
stress, patients with known CAD undergoing exercise stress
or patients undergoing adenosine stress were found to have
significantly higher event rates. With respect to patients
undergoing exercise stress, the risk associated with normal
MPS was similar in patients who achieved 85% and 80%
to 85% of MPHR, but HE rates were higher in patients
who achieved 80% of MPHR.
Multivariable survival models revealed that clinical factors
dramatically altered both the risk of HE and its temporal
characteristics, suggesting that clinical information yields
incremental prognostic value over MPS data in patients
with normal scans. Cox proportional hazards analysis iden-
tified adenosine stress, CAD history, diabetes, gender, and
increasing age as the model most predictive of HE, with
significant interactions between type of stress and CAD
history (lower risk in patients without previous CAD
undergoing exercise stress in comparison to all other pa-
tients) as well as between the presence of diabetes and
patient gender (higher risk in female diabetic patients
compared with all other patients). Parametric survival anal-
ysis in patients without previous CAD revealed that increas-
ing age, gender, the presence of diabetes, and adenosine
stress best predicted HE (with significant interactions be-
tween the presence of diabetes and patient gender [higher
Table 7. Time (Days) From Index Test to 0.5%, 1.0%, 1.5%, and 2.0% Predicted Risk of Hard Events in Patients With No History
of Previous Coronary Artery Disease
Age (yrs)
Time To: Time From:
0.5%
Risk
1.0%
Risk
1.5%
Risk
2.0%
Risk
Test to
0.5%
0.5% to
1.0%
1.0% to
1.5%
1.5% to
2.0%
Exercise stress
Male non-diabetic 50 1,725 3,287 4,801 6,292 1,725 1,562 1,514 1,491
60 1,406 2,679 3,914 5,129 1,406 1,273 1,235 1,215
70 815 1,553 2,269 2,974 815 738 716 705
80 336 641 936 1,226 336 305 295 290
Male diabetic 50 1,691 3,222 4,707 6,168 1,691 1,531 1,485 1,461
60 1,378 2,626 3,837 5,028 1,378 1,248 1,211 1,191
70 799 1,523 2,225 2,915 799 724 702 690
80 330 628 918 1,202 330 298 290 284
Female non-diabetic 50 2,680 5,106 7,459 9,774 2,680 2,426 2,353 2,315
60 2,184 4,162 6,080 7,967 2,184 1,978 1,918 1,887
70 1,266 2,413 3,525 4,619 1,266 1,147 1,112 1,094
80 522 995 1,454 1,905 522 473 459 451
Female diabetic 50 549 1,046 1,529 2,003 549 497 483 474
60 448 853 1,246 1,633 448 405 393 387
70 260 495 722 947 260 235 227 225
80 107 204 298 390 107 97 94 92
Adenosine stress
Male non-diabetic 50 677 1,290 1,885 2,470 677 613 595 585
60 552 1,052 1,537 2,014 552 500 485 477
70 320 610 891 1,168 320 290 281 277
80 132 252 367 482 132 120 115 115
Male diabetic 50 664 1,265 1,848 2,422 664 601 583 574
60 541 1,031 1,506 1,974 541 490 475 468
70 314 598 873 1,145 314 284 275 272
80 129 247 360 472 129 118 113 112
Female non-diabetic 50 1,052 2,005 2,929 3,838 1,052 953 924 909
60 858 1,634 2,387 3,128 858 776 753 741
70 497 947 1,384 1,814 497 450 437 430
80 205 391 571 748 205 186 180 177
Female diabetic 50 215 409 597 782 215 194 188 185
60 176 335 489 641 176 159 154 152
70 102 194 284 372 102 92 90 88
80 42 80 117 153 42 38 37 36
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risk in female diabetics compared with all other patients]).
In patients with previous CAD, the final model of time to
HE included increased age and gender, diabetes, and
previous catheterization.
Based on the parametric survival models, in patients
without previous CAD, predicted risk increased (and time
to any level of risk decreased) significantly with age, with
diabetes in women, and with adenosine stress. For any
combination of clinical factors, the level of risk in these
patients appeared to stay uniform with time (e.g., the risk in
the first 12 months post-MPS was the same as the second
12 months post-MPS). In patients with known CAD,
predicted risk also increased (and time to any level of risk
decreased) with age and in female diabetics. Importantly, for
any combination of clinical factors in patients with CAD,
risk increased with time. That is, the risk in the first year
was less than in the second year, hence, a dynamic temporal
component of risk was present. Of note, absolute predicted
risk was greater in patients with known CAD than in
patients without previous CAD.
Incremental prognostic value of clinical data. We previ-
ously suggested (4) that clinical characteristics influence
patient outcome after a normal scan based on the finding of
a trend of increasing HE rates in patients with normal scans
with post-ETT likelihood, Duke treadmill score, or increas-
ing age. Numerous studies have described the incremental
Table 8. Time (Days) From Index Test to 0.5%, 1.0%, 1.5%, and 2.0% Predicted Risk of Hard Events in Patients With
Known Coronary Artery Disease
Age (yrs)
Time To: Time From:
0.5% 1.0% 1.5% 2.0% Test to 0.5% 0.5% to 1.0% 1.0% to 1.5% 1.5% to 2.0%
Male non-diabetic 50 246 397 527 645 246 152 130 118
60 218 353 468 573 218 135 115 105
70 194 314 416 509 194 120 102 93
80 173 279 370 453 173 106 91 83
Female non-diabetic 50 3,781 6,114 8,111 9,922 3,781 2,333 1,997 1,811
60 276 2,064 2,737 3,349 1,276 787 674 611
70 431 696 924 1,130 431 266 227 206
80 145 235 312 381 145 90 77 70
Male diabetic 50 252 408 541 661 252 156 133 121
60 211 341 452 553 211 130 111 101
70 176 285 378 463 176 109 93 84
80 147 238 316 387 147 91 78 71
Female diabetic 50 199 322 427 522 199 123 105 95
60 197 319 423 518 197 122 104 94
70 196 316 420 513 196 121 103 94
80 194 314 416 509 194 120 102 93
Figure 5. Examples of predicted event rates in the first and second years after the index single photon emission computed tomography study. The top pair
of bars represents first- and second-year event rates in a 50-year-old male with no known coronary artery disease (CAD) undergoing exercise stress. In
comparison, an 80-year-old male with no known CAD undergoing adenosine stress would have significantly greater first- and second-year event rates. Of
note, although the risk increases, the rates in the first and second years are not different. On the other hand, the counterparts of these two patients with
CAD, as shown in the bottom two pairs of bars, would have significantly greater risk, the rate in the second year would exceed that in the first year, and
the change in risk between year 1 and year 2 would increase as a function of age in the setting of known CAD. Black bars  year 2 predicted hard event
rate. White bars  year 1 predicted hard event rate. Ad  adenosine; Ex  exercise; Hx  history; y.o.  year old.
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prognostic value of MPS data over clinical, historical, and
treadmill data for prediction of adverse events. The current
study reinforces the importance of the converse of this
finding—clinical and historical clinical information yields
incremental information over MPS data alone. This indi-
cates that for a normal MPS result, actual patient risk will
vary with clinical and historical data. This is consistent with
clinical intuition; with normal MPS, an elderly patient with
known CAD and revascularization who is unable to perform
exercise stress would have a greater risk than a young patient
with good exercise tolerance without previous CAD. This
information has long been incorporated in clinical practice,
as shown by the value of clinical data for predicting referral
to catheterization after MPS.
Previous studies: prediction of low risk versus defining
time intervals with low risk. Although a low risk is
associated with normal MPS (1–3,5–13), several recent
studies have reported somewhat higher event rates (14–18).
These rates are generally reported as both cumulative and
annualized event rates. As previously stated, an event rate of
3% over a three-year period may be due to: 1) a low constant
event rate, 2) an event rate of 1% in the first year and
increasing event rates in subsequent years, or 3) a much
higher event rate initially and a lower rate subsequently. To
date, post-MPS risk has not been reported as rates within
circumscribed time intervals after the index study, an ap-
proach that would yield insight into both the change in risk
over time and the duration of time after the study that risk
remains low. Although previous studies have reported
longer follow-ups (12,17), no previous reports have assessed
the change in risk over time.
Clinical implications. The relative differences between
therapeutic modalities with respect to mortality or cost vary
as a function of the post-intervention timepoint at which
they are examined. Although previous studies have shown
reductions in short- and long-term costs of care with the
addition of nuclear testing to a clinical strategy (1–3), these
studies assumed that patients would undergo no further
testing after a normal MPS. If repeat testing is needed or
resource utilization increases at a certain time interval after
a normal scan, the clinical- and cost-effectiveness of strat-
egies incorporating nuclear testing would be significantly
altered. However, to fully understand the cost implications
for testing strategies, inquiry into temporal variations in risk
with alternative testing strategies is necessary.
The finding that patients with a low likelihood of disease
referred to MPS are at low risk for a considerable time
interval after a normal study implies that these patients
probably do not require repeat testing for a number of years.
That patient characteristics alter the rate at which risk
develops after normal scans suggests that under certain
circumstances a reported annualized event rate may mises-
timate the actual risk. If risk is non-constant over the
follow-up period, the annualized event rate will differ from
the event rate in each year of the study. A non-constant
event rate was present in the current study in patients with
known CAD.
Study limitations. The patients in this study are those
referred to a university-affiliated referral center, potentially
limiting generalizability. The scintigraphic studies were
assessed by experienced observers using a standardized,
semiquantitative approach to visual interpretation (5,20).
The visual approach was used because at the time of
collection of the SPECT studies, we did not have a
quantitative analysis technique operating on all of our
camera/computer systems. However, the reliance upon the
expertise of the observer limits the extrapolation of our
results to those of other centers.
Although parametric survival models can accurately esti-
mate predicted time to risk and levels of risk at specific time
intervals, the limited number of events in this study com-
promises the precision of the estimates of risk and time to
risk in the current study. In the current study, these
estimates are intended to demonstrate the impact of the
variables in the model as confounders of risk and time to risk
in patients with normal scans.
Conclusions. The risk of HE after a normal MPS, and its
change over time, are a function of the clinical and historical
factors of the patients tested. Hence, clinical factors add
incremental value over MPS data alone and alter the time at
which repeat testing might be appropriate, hence establish-
ing the existence of a “warranty” period for normal MPS
studies.
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